ROQ
NEUTRALRoquefort Therapeutics Announces Annual General Meeting
The biotech company has announced the date and details for its upcoming Annual General Meeting.
Roquefort Therapeutics
1.8000GBX
5.88%
Market Cap
2.95M
Volume
6.29k
0% of avg
P/E Ratio
EPS (TTM)
Beta
-0.31
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p1.8000p6.7750p
1.8000p
Upcoming Events
ROQ
NEUTRALRoquefort Therapeutics Extends Convertible Loan Note Maturity
The biotech company has agreed with holders of its convertible loan notes to extend the maturity date to the end of 2025.
ROQ
NEUTRALRoquefort Therapeutics Provides Update on Corporate Transactions and Forward Strategy
The biotech company announces plans to sell two subsidiaries and pivot its focus towards acquiring clinical-stage assets or revenue-generating life science businesses.
ROQ
BADRoquefort Therapeutics Reports Annual Results Amid Ongoing Development and Financial Challenges
The pre-clinical biotech firm reported continued losses and declining cash reserves, despite progress in research programs. It's pursuing asset sales and new opportunities to generate short-term value amid funding challenges.
ROQ
BADRoquefort Therapeutics Raises £236,000 Through Discounted Private Placing
The biotech company has raised £236,000 through a private placing of new shares at a 6.25% discount, raising concerns about funding challenges and investor confidence.
ROQ
NEUTRALRoquefort Therapeutics Announces Board Transition
The biotech company announces a change in leadership, with the CEO resigning and a new Interim Managing Director taking over.
ROQ
NEUTRALRoquefort Therapeutics Announces Proposed Sale of Oncogeni Subsidiary
The biotech company announces the proposed sale of its Oncogeni subsidiary for up to US$12 million, aligning with its strategy of developing and monetizing pre-clinical assets.
ROQ
NEUTRALRoquefort Therapeutics Provides Update on Lyramid Sale
The biotech company provides an update on the sale of its subsidiary Lyramid to Pleiades Pharma, with the transaction still subject to Pleiades completing a fundraising.
ROQ
NEUTRALRoquefort Therapeutics Directors Increase Shareholdings
The biotech company's directors have purchased additional shares, suggesting confidence in the business, but the announcement lacks details on operations or financials.
ROQ
GOODRoquefort Therapeutics Sells Midkine Asset Portfolio for $10.8M
The biotech company has signed a deal to sell its Midkine asset portfolio for $10.8 million, allowing it to focus on developing its other promising programs.